Buy NAD+ injection: three formats, one sterility problem
If you set out to buy NAD+ injection material, the first thing to understand is that you are not choosing between brands. There is no approved NAD+ injectable product anywhere, so nothing on the market has a label, an NDC number or a manufacturer standing behind it. What you are choosing is a format, and the three formats differ far more in who takes responsibility for sterility than in what molecule is involved.
Format one is the IV bag at a drip bar or wellness clinic, compounded from a bulk substance by somebody other than you. Format two is the shot at that same clinic, which NPR reported in May 2026 can carry a price tag rising to several hundred dollars. Format three is a vial of lyophilized NAD+ bought as research material, which at the supplier we link is 1,000 mg at $104.00 list and $52.00 with the code PEPTIDEDECK.
Running through all three is a single problem that the price difference obscures completely. NAD+ is a coenzyme sold at industrial scale, and a great deal of the material in circulation was never made to go into a person. The sterility question is the whole of this page, and it is the reason a $52.00 gram and a $600 infusion can both be the wrong answer for the same reason.
We earn a commission on the vial link, which our affiliate disclosure covers in full. It has not stopped us writing the next section, which is the least flattering thing anyone selling NAD+ can put on a page.
| Format | Who prepares it | Typical cost | Who carries the sterility risk | Regulatory position |
|---|---|---|---|---|
| IV bag at a clinic or drip bar | A compounder, from a bulk substance | $200 to upwards of $1,000 a session (NPR) | The clinic and its bulk supplier | Compounded, not approved. NAD sits in FDA 503A category 1, under evaluation |
| Shot at a clinic | The same compounding chain | Up to several hundred dollars (NPR) | The clinic and its bulk supplier | Compounded, not approved |
| 1,000 mg research vial | Nobody. It ships as powder | $52.00 with the code | You, entirely | Research material, laboratory use only |
Three ways NAD+ reaches a person. None of them involves an FDA-approved NAD+ product.
The IV bag, and what FDA told compounders about it
FDA published a compounding notice, content current as of 10/30/2024, that is about this exact scenario. The agency wrote that it is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products.
It then explained why that matters, in one sentence worth reading twice: ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins, which can harm patients.
And then it recorded what happened. FDA has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, with some requiring medical treatment. The agency states that these reactions are consistent with excessive levels of endotoxins.
Read that against the setting. The people in those reports were not experimenting in a kitchen. They were, in the main, sitting in a clinic having paid a professional fee for a professionally prepared infusion. The format that looks safest by a distance is the one FDA felt the need to write about, because it is the format where a third party sourced the raw material and the customer never saw where it came from.
None of that means every drip bar is running food-grade material. It means the question has a documented reason to be asked, and that the person best placed to ask it is the one paying the invoice. The rules FDA points compounders to are not obscure either: under section 503A, bulk drug substances must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA, and the agency urges compounders to know their bulks supplier.
The NAD+ shot: what the clinic is putting in the syringe
The NAD+ shot buy decision is usually made in a waiting room rather than online, and it deserves the same two questions as the bag. Where did the bulk substance come from, and what grade was it. A shot is smaller and quicker than an infusion, but it comes from the same supply chain and the same compounding step.
There is a second question specific to the shot, which is what else is in it. Clinics frequently sell blends, and NPR's 2019 reporting described NAD therapy as an IV infusion that can contain amino acids and other nutritional supplements alongside nicotinamide adenine dinucleotide. If you are buying a shot on the strength of one ingredient, ask for the full composition in writing and the quantity of each component. A menu item name is not a formulation.
The third question is the one clinics answer least willingly: how many milligrams of NAD+ are you actually receiving. Without that figure, nobody, including the clinic, can compare one shot against another, and the price per session becomes uninterpretable. Our NAD+ price breakdown runs the arithmetic across formats and hits exactly this wall.
Buy NAD+ IV at a clinic, or buy the vial: what actually changes
The instinct is that the clinic route is the safe one and the vial is the risky one, and on most compounds that instinct is correct. NAD+ is the case where it holds up least well, and it is worth being precise about why rather than just contrarian.
What genuinely improves at a clinic: somebody trained prepares a sterile product, somebody qualified is in the room while it runs, the business carries insurance and a state licence, and there is a complaints route that leads somewhere real. If you have a reaction, the response is immediate rather than a search for an urgent care clinic.
What does not improve: the origin of the raw material, its grade, and whether anybody tested it for endotoxins. Those are decided upstream of the clinic, by whoever sold it the bulk substance, and they are invisible from the treatment chair. FDA's notice exists precisely because that upstream step went wrong often enough to generate adverse event reports.
And what gets worse in the clinic direction is exposure. An intravenous infusion delivers everything in the bag straight into the bloodstream over a sustained period, which is the least forgiving possible route for a contaminated preparation. That is not an argument for the vial. It is an argument that the sterility question is more urgent in the setting people assume is already handled.
This site has no interest in pretending the vial route is supervised, because it is not. It is a box of research powder with a laboratory-use label, and nobody is checking that it suits you. What it does have is a paper trail you can read before you open it, which is more than most people ever see at a drip bar.
Why the sterility bar is highest where people buy most casually
There is a pattern worth naming across this whole category. The more casual the purchase feels, the higher the actual sterility requirement, and the two move in opposite directions.
Booking a drip is easier than booking a dentist. It happens on an app, in a strip mall, sometimes at a music festival, and it is marketed as wellness rather than medicine. Nothing about the experience signals that you are about to receive an unapproved compounded sterile preparation intravenously. Yet that is technically what is happening, and it is the format with the least tolerance for a contaminated batch.
The vial, by contrast, feels illicit and arrives labelled for laboratory use, which at least sets the expectation correctly. Nobody buying one is under the impression that a regulator has cleared it.
That inversion is the practical argument for asking the clinic the same questions you would ask a research vendor. Grade, source, certificate, endotoxin result. A good clinic will not be offended, because a good clinic has already asked its own supplier. NPR's 2026 reporting also recorded something worth carrying into that conversation: in the pilot study run by the chief science officer of a national infusion chain, NAD+ infusions elicited moderate to severe abdominal cramping, diarrhea, nausea and vomiting. That was reported as part of the case that infusions appear safe, which tells you what the baseline experience is even when nothing has gone wrong.
Endotoxin testing: the one line to look for on a certificate
A certificate of analysis for NAD+ will usually show identity and purity, established by high performance liquid chromatography and often confirmed by mass spectrometry. Those tests answer the question of what the molecule is and how much of the sample is that molecule. Neither of them answers whether the batch is clean enough to put in a bag.
The test that does is a bacterial endotoxins assay, usually labelled LAL or bacterial endotoxins, reported in endotoxin units. Endotoxins are fragments of bacterial cell wall. They survive processes that kill bacteria, which is why a batch can be sterile and still cause the rigors FDA described. Sterility and endotoxin content are two different results, and a certificate can carry one without the other.
So the single line to look for is an endotoxin result with a numeric value and a limit. If it is absent, the certificate has not been falsified, it has simply not been asked the question that put people in a clinic chair shaking. Ask the vendor whether one exists for your batch, and ask the clinic the same thing about the bulk it compounded from.
The listing we link states that two independent laboratories test every batch, which is more testing than this market usually publishes. We have not been shown an endotoxin figure for the NAD+ batches specifically, so we are not going to imply one exists on your behalf. Ask, in writing, before you order. Our guide to judging an NAD+ source sets out the rest of the checklist, and if you want the same standard applied to prescribers rather than vendors, our safety companion covers how we assess providers.
| Test on the certificate | What it establishes | Does it answer the endotoxin question? |
|---|---|---|
| HPLC purity | How much of the sample is the stated compound | No |
| Mass spectrometry identity | That the compound is what the label says | No |
| Appearance and solubility | Basic physical conformity of the batch | No |
| Bacterial endotoxins (LAL) | Endotoxin load, reported against a limit | Yes. This is the line to look for |
| Sterility | Absence of viable organisms | No. Endotoxins survive when bacteria do not |
What each test on a certificate of analysis does and does not tell you.
What buying an NAD+ injection does not include
Whichever format you choose, the list of things absent from the transaction is the same, and it is longer than the list of things present.
No approved label, so no dosing instructions written by a manufacturer and reviewed by a regulator. No contraindication list. No interaction checking against anything else you take. No pharmacovigilance system attached to the product, although you can still report a problem to FDA through MedWatch, and if something went wrong you should. No recall mechanism that will find you if a batch is withdrawn.
We do not publish dosing, injection technique or reconstitution instructions on this site, and this page is not the exception. If that is what you came for, PeptideDosage handles the arithmetic at its NAD+ dosage page, and the laboratory handling maths at its NAD+ calculator.
One last honest note about the evidence, because a format comparison can imply the question of whether to buy at all has been settled. It has not. NPR's May 2026 piece concluded that the NAD+ products on the market are not proven to do the average person much good, and that there is almost no published data on the infusions specifically. Choosing the safest format for something with no demonstrated benefit is still a choice worth making carefully, but it is a different question from whether to make the purchase.